Explore innovative strategies for testing and treating HER2 alterations in non-small cell lung cancer through real-world case studies and expert insights.
Back
HER2 Alterations in NSCLC: Testing and Treatment Sequencing
Discuss evolving treatment landscape of HER2-directed therapies in NSCLC Evaluate sequencing strategies for HER2-targeted ADCs and TKIs Interpret the role of HER2 mutation and overexpression testing in clinical practice
HER2 Alterations in NSCLC: Testing and Treatment Sequencing
Episodes
All
All
Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges and responses to therapy in a patient with metastatic disease.
Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges, responses, and the importance of monitoring for ILD.
Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges and responses to chemotherapy and immunotherapy.
Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges, responses, and the importance of monitoring for ILD.
Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges, responses, and the importance of monitoring for ILD.
Explore innovative strategies for managing HER2 alterations in non-small cell lung cancer, including testing, treatment sequencing, and real-world case studies.
Explore a detailed case study on managing HER2-mutant non-small cell lung cancer, highlighting treatment strategies and progression monitoring.
Explore a case study on HER2 mutant lung cancer treatment, highlighting challenges, responses, and the importance of monitoring for ILD.
Explore a detailed case study on managing HER2-mutant non-small cell lung cancer, highlighting treatment strategies and progression monitoring.
Explore the complex case of a 70-year-old woman battling metastatic adenocarcinoma, highlighting treatment challenges and HER2 testing results.
Explore the complex case of a 70-year-old woman battling metastatic adenocarcinoma, highlighting treatment challenges and HER2 testing results.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
The OncFive: Top Oncology Articles for the Week of 8/2
3
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
4
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
5